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Abstract
Background: Neuropathic pain is one of the key features of (classical) Fabry disease (FD). No randomized clinical
trials comparing effectiveness of different pain management strategies have been performed. This review aims to
give an overview of existing pain management strategies.
Methods: PubMed and Embase were searched up to September 2014 for relevant articles on treatment of
neuropathic pain in FD.
Results: Seven-hundred-thirty-one articles were identified of which 26 were included in the analysis. Studies
reported on 55 individuals in total, with group-sizes ranging from 1 to 8. Carbamazepine appeared most beneficial:
complete pain relief in 5/25, partial relief in 17/25, and no benefit in 3/25 patients. Phenytoin resulted in complete
relief in 1/27, partial relief in 12/27 and no benefit in 6/27 patients. In 8 patients a significant reduction in the
frequency of pain attacks was described. Gabapentin caused partial relief in 6/7 and no relief in 1/7 patients. Little
evidence was reported for SSNRI’s or treatment combinations. Adverse-effects were reported in all treatment
strategies.
Conclusions: Only for carbamazepine, phenytoin and gabapentin there is evidence of effectiveness in neuropathic
pain due to FD, but comparison of effectiveness between these drugs is lacking. In routine clinical practice adverse-
effects may discourage use of carbamazepine and phenytoin in favor of second-generation antiepileptic drugs, but
this is currently not supported by clinical evidence. This review suffers greatly from incomplete outcome reports
and a predominance of case reports, which emphasizes the need for robust clinical trials and observational cohort
studies.
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Background
Fabry disease (FD, OMIM 301500) is a rare X-linked inher-
ited lysosomal storage disease caused by a deficient or de-
creased activity of the lysosomal enzyme α-galactosidase A,
as a result of a mutation in the GLA gene. The consecutive
accumulation of glycosphingolipids, mainly globotriaosyl-
ceramide (Gb3), in lysosomes of several cell-types results in
kidney, heart and nervous system complications [1]. FD is a
heterogeneous disease with phenotypes ranging from
severe, ‘classical’ FD to the more attenuated ‘non-classical’
form of the disease. Classically affected patients usually
present at an early age with neuropathic pain, hypo- or
anhidrosis, disseminated angiokeratoma, cornea verticillata,
and microalbuminuria. At a later age, progressive damage
to kidney, heart and brain may occur [2]. Patients with a
‘non-classical’ phenotype often have milder disease, and
signs or symptoms may be limited to only one organ. The
estimated prevalence of classical FD is 1 in 40.000 live
births [3]. When non-classical and other GLA variants late-
onset variants are considered, the prevalence may be as
high as 1:1250 [4].
Neuropathic pain is one of the key features of the clas-
sical phenotype of the disease and has been shown to
start on average at an age of 9 years in male patients and
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16 years in female patients [5], but has even been re-
ported in children as young as 2 years of age [6]. The
pathophysiology of pain in FD is still poorly understood.
Small fiber neuropathy (SFN) as a result of glycolipid ac-
cumulation in either the dorsal root ganglia or the endo-
thelial cells of the blood vessels supplying the nerve
fibers have been proposed as possible mechanisms [7].
Others have hypothesized that lysoGb3 (globotriaosyl-
sphingosine, a deacylated Gb3 molecule) may exert a
direct pathological effect on the ganglia or axons of Aδ
fibers [8]. This hypothesis is supported in a recent study
where a direct link between lysoGb3, increased intracel-
lular Ca2+ levels in peripheral sensory neurons and pain
was shown [9]. Whether this is causally related to small
nerve fiber damage remains unclear [9].
Two types of pain often co-occur in classical FD:
chronic pain in hands and feet and severe episodic pain at-
tacks, also referred to as ‘Fabry crises’ [10, 11]. The latter
are usually triggered by sudden changes in environmental
or body temperature, and may persist for minutes to
weeks [12]. The chronic pain is often described as burn-
ing, shooting or tingling pain, with a low to severe inten-
sity. Both types of pain have been reported to be major
causes of morbidity during the first 2 decades of life [13].
Moreover, research has shown that there is a strong asso-
ciation of chronic pain with depression [14]. As pain is a
key feature in patients with FD an increased risk of
depression is likely [15, 16]. It is therefore of importance
to treat neuropathic pain adequately.
Treatment of neuropathic pain in FD starts with prevent-
ive measures and lifestyle changes, such as avoiding precipi-
tating factors (physical exercise, exposure to sun or heat).
Conservative therapy includes rest, holding icepacks, or ad-
ministration of acetaminophen during febrile periods. Apart
from these measures, additional pharmacological pain man-
agement is often necessary. A wide range of pain medica-
tion has been reported in the treatment of neuropathic
pain in patients with FD. Gold et al. [15] report on a cohort
of FD patients (n = 53) of whom 51 % uses pain medication,
chronically. In a post-marketing registry study, 71 % of pa-
tients used analgesics, 36 % used anticonvulsants and 23 %
used NSAIDs [17]. Furthermore the routine use of prophy-
lactic medication has been reported in 23 patients including
acetaminophen, carbamazepine, phenytoin and valproate
[18]. Despite all the different analgesics that are prescribed
in FD, the response to these regimens often remains unsat-
isfactory [19]. The current mainstay of therapy has been
based on the long-term use of antiepileptics such as carba-
mazepine, gabapentin or phenytoin [20]. Nevertheless, little
is known about its safety and effectiveness in patients with
FD as no large-scale clinical trials or cohort studies have
been performed to date. As a result, most data available
come from small, uncontrolled, observational studies on
less than 10 patients each. Here we report the results of a
systematic review on the effectiveness and the adverse
effects of different pain management strategies to treat
neuropathic pain in FD. Our findings could serve as a
rationale for controlled trials. We also aimed to develop a
treatment algorithm for chronic and acute pain manage-
ment in patients with FD.
Methods
Literature search
PubMed and Embase were searched from 1947 until
September 2014 for relevant studies and reports on pain
management strategies for neuropathic pain in FD. Key
terms used were ‘Fabry disease’ and ‘pain’, including al-
ternative notations. Also, ClinicalTrials.gov was searched
to identify additional published or unpublished data.
Additional reports were identified by hand searching the
reference lists in the retrieved papers.
Study selection
We included clinical trials, case series and case reports
on the effect of pain medication in children as well as
adults with FD and neuropathic pain. Studies on the
effect of ERT on pain and reviews were not included in
this review. Furthermore, studies lacking data on outcome
were excluded. Articles reporting only on analgesics (acet-
aminophen and NSAIDs) were excluded, because these
are known to be ineffective in the treatment of neuro-
pathic pain in FD and the renal involvement due to FD
makes NSAIDs unsuitable for chronic use in these
patients. Title and abstract of all identified studies were
read. If considered relevant, full text was read and ana-
lyzed. Data on pain severity and number of patients
treated, drug and dosing regimen, study design, study dur-
ation and follow up, outcome measures and results, with-
drawals and adverse events were extracted by one author
(YS). As primary outcome we recorded chronic pain re-
duction after any treatment period as assessed in each
study. Pain reduction was classified as complete relief of
pain, partial relief of pain and no effect on the scale used
in each study. As secondary outcome measures we
recorded i) reduction of the frequency of pain attacks as
reported by the patient, ii) any pain related outcome
indicating improvement or worsening, iii) treatment with-
drawals due to lack of effect, and iv) any (serious) adverse
event while on treatment.
Results
Literature search results
The search provided 728 articles (Fig. 1, study flow dia-
gram). Three additional articles were found by searching
the reference lists [17, 21, 22]. We excluded 629 articles
after screening of title and abstract. One hundred and
two articles were read in full text, of which 76 were sub-
sequently excluded. Forty-eight of these 76 articles were
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considered to be less relevant, because referrals to
other studies were made, no information was provided
about analgesic treatment, or only conservative pain
management (e.g., rest, holding ice packs) was
described [11, 18, 20, 23–38]. Twenty-seven articles
provided information on pain management, but details on
outcome were lacking. One case report describing a male
patient using carbamazepine was excluded [39]. This 34-
year old male carried a GLA variant (A143T) which is
generally considered a polymorphism based on normal
biopsy results and normal lysoGb3 levels in individuals
carrying this variant [40–42]. He had a 5-year history of
activity-induced foot and leg cramps and fasciculations
with pain, which is not a typical presentation of FD neuro-
pathic pain, while the intraepidermal nerve fiber density,
kidney biopsy and cardiac and brain investigations were
all normal. Taking the controversial mutation and his clin-
ical picture together, we considered his symptoms not to
be caused by FD.
Twenty-six studies were included in the final analysis
and these reported on 55 patients in total [21, 43–67].
Patients were 3-45 years old, and at least 15 patients
were below 18 years of age. An exact number could not
be calculated due to the lack of data in the majority of
included studies. Case-reports predominated; only 7/26
reports included more than 1 patient. None of the stud-
ies were randomized controlled trials. Three studies
were performed with the specific aim to evaluate the
effectiveness of a treatment for neuropathic pain in FD
[43, 49, 53]. Treatment group sizes were small, ranging
from 1 to 8 patients per report. A variety of different
pain assessment tools was reported, including visual
analogue scales (VAS) (4 %), the brief pain inventory
(BPI) (4 %), pain relief scores (8 %), or other subjective
pain scoring tools (84 %). The majority of studies (84 %)
did not specify study duration. Where mentioned, most
studies were of relatively short duration: individual treat-
ment periods ranged from several days (case reports) to
up to 5 years (observational studies). Details of included
studies are reported in Table 1.
Pain management strategies and effects
The following analgesics were used: carbamazepine,
gabapentin, phenytoin, neurotropin and opioids Results
of all pain strategies are summarized in Table 1.
Carbamazepine was used in 27/55 patients (49 %,
reported in 18 studies), most often as mono-therapy (25
patients, 44 %, reported in 17 studies). Patients used
carbamazepine dosages of 100-600 mg/day, or 0.8-
15.9 mg/kg/day. Complete relief of pain was described in
5 of the 25 patients on mono-therapy [43, 58, 61, 67],
partial relief in 16 patients [43, 46–48, 52, 54, 55, 57, 59,
60, 62, 63, 65] and no effect in 3 [43, 67]. Additionally, 1
patient reported a reduced frequency and duration of
crises. Four of the 25 patients were treated simultan-
eously with enzyme replacement therapy (ERT) and all
showed partial pain relief. The effect of carbamazepine
was confirmed by a double-blind cross-over design in
one patient [54]. It was started with a daily dosage of
200 mg, which was enough to suppress the pain. Substi-
tution by placebo was followed by a reappearance of the
excruciating pain within 48 h, and readministration of
the drug relieved the pain completely. In the same pa-
tient, the effect appeared faster and lasted longer than in
the case of phenytoin [54]. Oral administration of carba-
mazepine was only partially helpful in alleviating the
shooting pain in one patient (reported in two studies), but
after treatment with neurotropin orally in addition to
carbamazepine, the constant paresthesia and episodic
shooting pain disappeared almost completely [45, 46].
Other combination strategies resulted in complete pain
relief with gabapentin and carbamazepine in 1 patient
[45]. Gabapentin alone was ineffective in a study by Park
et al., but it should be noted that it was discontinued after
just 2 days. Subsequently, a combination of phenytoin and
carbamazepine was administered, which caused partial
pain relief [51]. Gabapentin monotherapy has been
Fig. 1 Study flow diagram. Numbers of studies screened, assessed
for eligibility, and included in the review
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Table 1 Results of individual studies. This table gives an overview of the characteristics of each study included in the review, and
summarizes the main endpoints
Study (N, sex) Medication Dose Effectiveness recorded chronic pain reduction






Monotherapy – primary endpoint
Patil [52]
(N = 1, male)




(N = 2, 1 male)




? No response No response
(N = 1)
Lim [48]
(N = 1, male)
Carbamazepine
(+ERT)




(N = 1, female)
Carbamazepine 10 mg/kg/day
(23 kg)




(N = 1, male)









60 % improvement on questionnaire






Subjective improvement (25 %
improvement on questionnaire on





Absence of breakthrough pain,
questionnaire results improved




(N = 1, male)




(N = 1, male)




(N = 1, male)




(N = 1, male)







(N = 1, male)




(N = 1, male)




(N = 7, males)
Carbamazepine 0.8-15.9 mg/kg/day Partial amelioration in 3 patients (43 %),
complete pain relief in 2 patients (29 %),













[47, 57] (same patient)
(N = 1, male)




(N = 1, male)




(N = 1, male)
Phenytoin 5 mg/kg/day Ineffective No effect Discontinuation
Paira [50]
(N = 1, male)
Phenytoin 300 mg/day Pain controlled Partial pain
relief
Not reported
Phenytoin Inadequate pain control (5/5 patients) Not reported
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described in one other study in which 6 patients were in-
cluded. All of these patients showed a partial relief of pain
on an average daily dose of 917 mg [53].
In a study by Filling-Katz, 5 of 7 patients on carbamaze-
pine therapy had a history of phenytoin use [43]. Pheny-
toin at therapeutic dosages provided inadequate pain
control by patient report in all 5 subjects. The effect of
phenytoin was reported in an additional 22 patients (in 7
studies), with a dose range of 100-400 mg/day. Complete
pain relief was achieved in 1 patient, and partial pain relief
in 12 patients. Phenytoin was ineffective in 6 patients,
even though treatment duration ranged from 6 months to
5 years [43]. In 8 patients a significant reduction in the
frequency of pain attacks was described [56].
Table 1 Results of individual studies. This table gives an overview of the characteristics of each study included in the review, and
summarizes the main endpoints (Continued)
Filling-Katz [43]






(N = 2, 1 male)
Phenytoin Not reported Pain controlled in both patients Partial pain
relief (N = 2)
Not reported
Duperrat [66]
(N = 1, male)




(N = 8, 7 males)
Phenytoin 300 mg/day or
4-6 mg/kg/day
Average pain relief score of 2,7
(complete pain relief, p < 0,001
when compared to ASA or placebo)
Partial pain
relief (N = 8)
Dizziness, drowsiness
and headache in 1
patient
Shibasaki [54]
(N = 1, male)




(N = 1, male)
Gabapentin Not reported Pain persisted No effect Not reported
Ries [11, 53]
(N = 6, males)
Gabapentin Average daily dose
917 mg (range
100-1200 mg)
Average pain scores decreased from 5.0
(range 4-6) to 3.7 (range 3-6) with an
intraindividual reduction of 1.3 (range 0-3)
(p = 0,22)
Partial pain
relief (N = 6)
Generally well
tolerated. Vertigo and
blurred speech in 1
patient
Inagaki [46] + Inagaki
[45] (same patients)
(N = 2, males)
Neurotropin 4 units (crisis) Pain almost completely eliminated Partial pain
relief (N = 2)
Not reported
Wise [21]
(N = 2, males)
Pethidine 500-700 mg/day
i.m.
Pain reasonably controlled Partial pain




Lidocaine 2 mg/kg i.v. Quick pain relief in pain crisis Partial pain
relief (N = 2)
Combination therapies – primary endpoint
Park [51]













Pain decreased Partial pain
relief
Gordon [44]




0.06 mg/kg IV push,
0.02 mg/kg/hr IV;
0.25 mg/kg p.o. at
bedtime





Inagaki [46] + Inagaki
[45] (same patients)





Pain disappeared almost completely Partial pain
relief (N = 2)
Not reported
Monotherapy - Secondary endpoints
Gordon [44]
(N = 1, male)
Carbamazepine ? Reduced frequency and duration of crises
(to 3-4 times annually)
Partial pain
relief (N = 1)
Not reported
Spence [56] (N = 8,
males)
Phenytoin 100-400 mg/day Significant reduction in frequency of painful
crises in 7/8 patients
Partial pain




Abbreviations: ERT enzyme replacement therapy, eod every other day, CMZ carbamazepine, p.o. per os
Note: some studies are mentioned more than once due to use of several pain management strategies
Results stating ‘pain controlled’ interpreted by authors as ‘partial pain relief’
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One study published in 1962 described the use of
pethidine in 2 male patients, in whom partial pain relief
was achieved with 500-700 mg/day IM [21]. Another
study reports beneficial effect on pain during a crisis
with intravenous lidocaine [67].
Adverse effects
Three out of 20 studies including 4 patients reported on ad-
verse effects of carbamazepine. Dose-related autonomic
complications were reported in 2 patients, and necessitated
dose reduction in 1 patient and discontinuation in the other
[43]. Carbamazepine was discontinued because of drowsi-
ness in 1 patient [62]. One patient had no adverse effects of
carbamazepine [54]. Vertigo and blurred speech were
reported in 1 patient treated with gabapentin, which disap-
peared upon dose reduction [53]. In the same study, it was
stated that gabapentin was tolerated generally well in the
other patients. The other study on patients using gabapen-
tin did not report on adverse effects. Only 1 out of 8 studies
in which phenytoin was used (n = 27 patients) reported on
adverse effects. In this study 1 patient suffered from dizzi-
ness, drowsiness and headache [49]. Furthermore, discon-
tinuation was reported for phenytoin because of poor
compliance in 1 patient [44]. Few adverse effects (not
further specified) were reported on the combination of
neurotropin with carbamazepine in 1 patient [45].
Discussion
This systematic review of the literature on neuropathic
pain management in FD clearly demonstrates that cur-
rently available effectiveness data are mainly derived from
case reports and small observational studies. This is disap-
pointing when considering the high prevalence of chronic
pain in patients with FD and the fact that analgesics are
frequently prescribed by caregivers. Apparently, most phy-
sicians treating patients with FD have local procedures,
based on either treatment protocols for painful neuropa-
thies not specific for FD, or personal experiences. Of these
drugs, anti-epileptics, including carbamazepine, gabapen-
tin and phenytoin appear to be prescribed most often.
Based on this review we conclude that there is class IV
evidence that carbamazepine and phenytoin are effective
in the treatment of FD neuropathic pain, although it re-
mains unclear to which extent. This is in agreement with
previous reviews reporting on drug use for neuropathic
pain in FD [37, 68]. For amitriptyline, pregabalin and
lamotrigine there appears to be no evidence, insufficient
evidence, or even evidence of a lack of effect. For gabapen-
tin there was so little evidence that no sensible judgment
could be made about its effect on neuropathic pain in FD
patients, even though it is frequently prescribed in
patients with FD. Adverse-effects were seen in all
reported drugs, varying from dizziness (phenytoin), to
vertigo (gabapentin) and autonomic complications
(carbamazepine).
Implications for practice
As is evident from this review, the literature does not pro-
vide an answer to the important pragmatic question which
drug should be prescribed for the treatment of neuro-
pathic pain in FD. In addition, there is no sound evidence
in which order drugs should be evaluated. Clinical practice
has shown that most patients may achieve good results
with carbamazepine or phenytoin. Phenytoin, however, is
known to be associated with a number of potentially
troublesome adverse events, including neurologic and
hematologic effects [69]. In addition, there is an increased
risk of teratogenicity for both carbamazepine and pheny-
toin. The teratogenic potential of the newer antiepileptic
drugs and antidepressants in still unclear; small sample
sizes and exposure to multiple drugs have precluded a def-
inite conclusion so far. It is therefore important to discuss
carefully and tailored to each patient, the benefit and risks
of each drug for mother and fetus [70–72]. Both carba-
mazepine and phenytoin are known to be broad-spectrum
enzyme inducers by stimulating the activity of many
cytochrome P450 (CYP) enzymes (CYP2B6, CYP2C9,
CYP3A4 and CYP1A2) [73]. They can therefore reduce
the effectiveness of several co-administered medications,
such as statins (simvastatine, atorvastatine), SSNRI’s
(duloxetine, venlafaxine), (dihydropyridine) calcium antag-
onists (e.g., amlodipine, nifedipine), angiotensin receptor
blockers (ARBs) (losartan, candesartan, irbesartan), anti-
coagulants (warfarin) and steroids [74]. Taking into
account that the incidence of kidney- and heart-related
comorbidities is high in FD patients, interaction with
calcium antagonists and ARBs is inconvenient.
Vice versa, other commonly prescribed drugs in patients
with FD (fluoxetine, verapamil, amiodarone) may increase
the serum concentration of phenytoin and carbamazepine
by inducing CYP enzymes [75]. In women with neuro-
pathic pain, it is important to note that carbamazepine, as
well as phenytoin, increase the clearance of contraceptive
hormones, which may lead to contraceptive failure. The
use of carbamazepine and phenytoin is further limited by
their potential to cause undesirable side-effects, such as
gastrointestinal complaints and cytopenia. In addition, the
need for laboratory monitoring (sodium, leukocytes, trans-
aminases) in patients on carbamazepine resulted in prefer-
ence for newer antiepileptic drugs, such as gabapentin and
pregabalin. These are excreted unchanged through the
kidneys with no reliance on liver metabolism. Therefore
they do not lead to stimulation of the CYP enzymes and
lower concentrations of other drugs as carbamazepine
does [76]. On the other hand, the excretion by the
kidneys results in the need for a dose reduction in
renal insufficiency, one of the features of FD [77].
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Since pharmacokinetics of gabapentin are nonlinear, dosing
requires careful titration [76]. Pregabalin has pharmacoki-
netic advantages to gabapentin as it has linear pharmaco-
kinetics. Consequently, dosing is more straightforward and
requires only a twice daily administration [78]. The effect-
iveness and tolerability of pregabalin seem to be similar to
those of gabapentin. Both drugs are fairly well tolerated.
Dose-dependent dizziness and sedation can easily be
reduced by starting with lower dosages and dose titration.
However, although pregabalin and gabapentin are widely
prescribed and effective for neuropathic pain in general,
little is known about their effect in FD neuropathy [79].
Little has been reported about the use of dual serotonin
and norepinephrine reuptake inhibitors such as venlafax-
ine and duloxetine in treating neuropathic pain due to FD.
Duloxetine has shown consistent effectiveness in painful
diabetic peripheral neuropathy, with effectiveness sus-
tained for 1 year in an open-label trial [80]. Unfortunately,
duloxetine has not been studied in other types of neuro-
pathic pain, and so its effectiveness in such conditions is
unknown. Besides, both duloxetine and venlafaxine have
potential concomitant and undesirable adverse-effects in
patients with FD because of their anti-cholinergic effect
(e.g., constipation, anhydrosis, palpitations) [68]. Finally,
opioids are shown to be effective in the treatment of pain-
ful crises [44], but it should be noted that the chronic use
of opioids may cause obstipation, dependence, drowsiness
and involves the risk of substance abuse.
Most of the medications we have discussed provide only
partial pain relief, and adverse effects may limit dose escal-
ation. Hence, in clinical practice, it would make sense to
use 2 or more medications in combination in order to
achieve either an additive beneficial effect or a reduction
in the adverse effects associated with the use of a high
dose of a single drug. However, little evidence is available
to support the use of such combinations. Recently, com-
bination therapy is advised if at least two monotherapies
failed to relieve pain in FD [37]. A treatment algorithm is
proposed, which advises second generation antiepileptics
(pregabalin, gabapentin) to be used as medicines of first
choice. Drugs of second and third choice were phenytoin,
carbamazepine, and duloxetine. On the contrary, a report
of an expert panel on the treatment of neuropathic pain in
FD recommends carbamazepine as the drug of first
choice. Anticonvulsants and antidepressants are also con-
sidered viable options [68]. Due to the limited amount of
evidence with respect to the effectiveness of pain medica-
tion in FD, clinicians are often forced to rely on general
neuropathic pain protocols. In a recently published meta-
analysis about pharmacotherapy for neuropathic pain in
adults, which included 229 studies, a strong recommenda-
tion was given for tricyclic antidepressants (amitriptyline),
serotonin-noradrenaline reuptake inhibitors (duloxetine,
venlafaxine), pregabalin, and gabapentin as first line
treatment for neuropathic pain. Recommendations about
carbamazepine were inconclusive [81]. Another guideline
for the pharmacological management of neuropathic pain
recommends duloxetine, venlafaxine, gabapentin, pregaba-
lin and topical lidocaine as drugs of first choice. Opioids
are recommended as drugs of second choice, and carba-
mazepine as drug of third choice [76].
Since conditions that cause neuropathic pain in children
are relatively uncommon, data on general neuropathic
pain treatment in children are limited by small numbers
and few randomized controlled trials, leaving clinicians
with many unanswered questions regarding clinical prac-
tice [82]. It is unclear if generalization of interventions
used for neuropathic pain in adults may be appropriate.
Therefore, trials are needed on both the safety and efficacy
of drugs for the treatment of neuropathic pain in children
[82, 83]. Despite the paucity of evidence, a treatment algo-
rithm for the treatment of neuropathic pain in children
with FD was published. It discusses the use of carbamaze-
pine, antidepressants and anticonvulsants and includes
dosing and titration schemes [84].
Although evidence exists suggesting that some diseases
causing neuropathic pain respond differently to the same
medications [85], we can conclude that it seems inevitable
to base a treatment algorithm for FD patients for the
greater part on experiences with neuropathic pain in
general.
Taking all these findings and considerations into ac-
count we developed a treatment algorithm for pain man-
agement in patients (adults as well as children) with FD at
our hospital (Academic Medical Center, Amsterdam, The
Netherlands). In line with the expert panel report [68], the
included studies in this review and our own clinical expe-
riences, carbamazepine is considered the drug of first
choice. In case of treatment failure or contraindications,
we consider second generation anti-epileptics to be proper
drugs of second choice. Drugs of third choice include
SSNRI’s such as duloxetine and venlafaxine. In Appendix 1,
an overview of all agents is presented.
Role of enzyme replacement therapy
Studies on the effect of ERT on neuropathic pain have
shown conflicting results. Agalsidase alfa reduced the se-
verity of neuropathic pain in a randomized controlled trial
(RCT), but an imbalance in baseline pain scores hampers
the interpretation of the results [86]. A RCT on the effect
of agalsidase beta showed a significant reduction in pain
in both the treatment and the placebo group [87]. Several
observational studies showed no reduction of pain severity
with ERT [87–90], while there is some evidence that ERT
has a positive effect on pain in children [31, 91].
Altogether, it remains unclear whether ERT has an effect
on the neuropathic pain in patients with FD. Recently
published European recommendations for initiation and
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cessation of ERT in FD indicate that ERT should be con-
sidered in patients with neuropathic pain, and may even
be considered if the pain is completely controlled with
pain medication [2]. The formulation of this recommen-
dation implies that the decision to start ERT should be
made on an individual basis taking into account FD fea-
tures and personal preferences. In clinical practice, physi-
cians will often start with pain management, for which the
current algorithm can be of help to try to achieve max-
imum response. However, for future research, it would be
interesting to conduct a properly designed study to clearly
evaluate the effectiveness of ERT with or without concur-
rent use of pain medication on neuropathic pain.
Limitations
The predominance of case-reports in this review has to be
considered as a source of bias and therefore caution is
needed in interpreting the data. Meaningful comparison
of effectiveness with other interventions is not possible. In
addition, this review suffers greatly from the lack of details
provided in the case reports and case series.
Conclusion
Perhaps the most important conclusion of this review is the
need to perform large, high quality, long duration studies
using robust endpoints that actually measure effectiveness
of different analgesic drugs in FD neuropathic pain. It
would be of particular interest to compare first generation
(carbamazepine, phenytoin) with second generation antiepi-
leptics (pregabalin, gabapentin). Such a study would require
a uniform group (preferably classically affected males), and
an easily interpretable clinical endpoint (e.g., changes in
VAS or Brief Pain Inventory score) for an extended period
of time. As soon as such study results are published we will
be able to update the currently presented treatment
algorithm.
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